PhagoMed Biopharma GmbH is a pre-clinical biotech company focused on accelerating the re-introduction of phage therapy into Western medical practice. PhagoMed builds on the treatment expertise of its co-founders Prof. Dr. Wippermann and PD Dr. Trampuz, who have jointly treated ~20 patients with bacteriophages as a last resort over the past 15 years. As of early 2018, PhagoMed has completed its seed financing round (private investment
ViruSure is a privately owned biotech company specialising in the virus and prion safety testing of biopharmaceutical products. We offer contract testing services and a wealth and breadth of expertise to ensure you meet all relevant pathogen safety testing requirements. Our goal is to ensure that the strategy we develop with you will provide a high chance of success in satisfying all regulatory requirements at the first attempt.
Akribes Biomedical is dedicated to the improvement of chronic wound therapy. We developed the first theranostic assay platform to enable personalized pharmacological therapy of chronic wounds. Based on this platform we identified and patented drugs with so far unknown potential for chronic wound healing, which will be developed as novel wound therapeutics.
Our mission is to make a novel therapeutic approach a reality in Peritoneal Dialysis (PD) – an area where clinicians and patients saw disappointingly little innovation in decades. Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial.
APEPTICO Forschung und Entwicklung GmbH is a privately-held development stage biotechnology company in Vienna, Austria, developing peptide-based products targeting life-threatening pulmonary diseases.
THT Biomaterials GmbH aims to overcome major methodological issues at the bottom of today’s drug development, tissue engineering and regenerative medicine research practices leading to false positive or negative results. A new visionary platform technology is under development that will speed up research as it makes its results more realistic by replacing animal components with human components (https://tht-biomaterials.com).
Marinomed is a biopharmaceutical company specialized on innovative products based on the patent protected technology platforms Marinosolv® and the Carragelose®. The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds with the lead product Budesolv having successfully completed a pivotal Phase III study. The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract including SARS-CoV-2.
SAICO is a Vienna-based company founded in 2017 that focuses on the microfabrication of biosensors and lab-on-a-chip systems for biomedical applications. We facilitate the rapid translation of academic innovations into industrial production of diagnostic tools for personalized medicine. Our core competence is the rapid and cost-efficient generation of functional prototypes needed to reduce the development time from initial idea to market-ready devices.
Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)
YASARA Biosciences develops and distributes the YASARA molecular modelling and simulation program. This acronym stands for Yet Another Scientific Artificial Reality Application, and delineates the software's main purpose: to create an artificial reality inside the computer, atom by atom, visualize it in 3D and let the user interact with it. The focus has always been on biomolecular modelling, covering the most prominent topics (including structure prediction and docking).
Acticell is a research company that develops innovative solutions for new trends in the textile industry. The research and technology start-up has specialized in the field of cellulose chemistry, especially in the textile industry. Acticell know-how can replace life-threatening sandblasting and the environmentally harmful potassium permanganate in bleaching jeans. Worldwide leading jeans labels already rely on production processes with Acticell technology.
Ares Genetics is a sequencing service provider and bioinformatics developer revolutionizing how we address the global challenge of antimicrobial resistance (AMR). Ares Genetics enables better infection control and more targeted patient care by providing unprecedented insight into pathogens and AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
Microsynth Austria ist eine österreichische Tochtergesellschaft der Microsynth AG und befindet sich im Biotechnology Center Leberstrasse in Wien. Die Muttergesellschaft hat ihren Hauptsitz in Balgach, Schweiz, und betreibt weitere Tochtergesellschaften in Deutschland (Microsynth Seqlab) und der Schweiz (Ökogenik). Insgesamt beschäftigt Microsynth rund 100 Mitarbeiter.
NBS-C BioScience is a Contract Research Laboratory founded 2009 as a spin off by leading scientists of the Novartis Institutes for BioMedical Research in Vienna, Austria. In a second business field NBS-C BioScience develops and commercializes research tools and kit components for allergy research and diagnostics.
usePAT offers add-on devices for the improvement of in-line measurements in PAT (Process Analytical Technology) systems. They are compatible with a variety of sensors and can be designed and adapted to the specific needs and requirements of many fields of application. In order to facilitate the process of real-time measuring, our technology takes advantage of well-controlled ultrasonic fields for spatial particle manipulation in liquids.
Core areas of expertise are design, development and production of real-time PCR-based tests for the detection of various pathogens such as bacteria, viruses, fungi and parasites, for applications in human and veterinary medicine.
enGenes Biotech develops customized solutions for the cost-effective production of recombinant proteins and plasmid DNA in microbial expression systems. The company’s unique, proprietary, E. coli-based enGenes-X-press technology platform achieves outstanding yields of soluble and active recombinant protein or plasmid DNA by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.
Based on a highly innovative therapeutic concept ProFem develops new medicines for gynecological diseases which are characterized by a hitherto unmet medical need and high market potential. ProFem’s activities are currently focused on infectious diseases of the female lower genitourinary tract associated with the growth of biofilms.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.